Trials / Completed
CompletedNCT00133198
Efficacy and Safety of Pramipexole Compared to Placebo in the Treatment of Restless Legs Syndrome (RLS)
A Randomized, Double-blind, Placebo-controlled, Parallel Group Clinical Trial Comparing Fixed Doses of 0.25 mg, 0.50 mg and 0.75 mg Pramipexole (Mirapex®) Administered Orally to Investigate the Safety and Efficacy in Patients With Idiopathic Restless Legs Syndrome for 12 Weeks
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 345 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
A 12 week clinical trial was conducted in the United States in order to compare pramipexole (Mirapex®) versus placebo for the ability to reduce the symptoms of restless legs syndrome in adult subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pramipexole |
Timeline
- Start date
- 2004-04-01
- Primary completion
- 2005-02-01
- Completion
- 2005-02-01
- First posted
- 2005-08-23
- Last updated
- 2013-11-08
Locations
44 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00133198. Inclusion in this directory is not an endorsement.